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Abstract
The aim of this study was to evaluate the cardiovascular and renal activities of a newly designed natriuretic peptide (NP).
Here, we engineered a novel 28-amino acid chimeric peptide, termed AC-NP that combined the 17-amino acid ring of C
type natriuretic peptide (CNP) with the 6-amino acid N-terminus and 5-amino acid C-terminus of atrial natriuretic peptide
(ANP). Both in vitro and in vivo experiments were performed to determine the actions of AC-NP. In normal rats, AC-NP
proved to be more potentially diuretic, natriuretic and hypotensive compared with other NPs, such as ANP, CNP and
vasonatrin peptide (VNP), which is another man-made NP. In relaxation of isolated abdominal aorta from rat, AC-NP was
equally effective to ANP, CNP and VNP. Elevated levels of 39,59-guanosine monophosphate (cGMP) in plasma and urine
cGMP excretion indicated the participation of cGMP in the functions of AC-NP. Taken together, innovative designed AD-NP
might be a new candidate therapeutic peptide against cardiorenal disorders.
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Introduction
Human natriuretic peptides (NPs) are a family of structurally
similar but genetically distinct peptides including atrial natriuretic
peptide (ANP), brain natriuretic peptide (BNP), and C type
natriuretic peptide (CNP). NPs are known to play important roles
in the regulation of cardiorenal homeostasis [1]. ANP is a 28-
amino acid peptide, whereas BNP contains 32 amino acids, and
CNP contains 22. All of them have a 17-amino acid ringed
structure, which has been identified as essential for their
pharmacological activity [2]. Most functions of NPs appear to be
mediated through the elevation of intracellular cyclic 39,59-
guanosine monophosphate (cGMP) after their binding to natri-
uretic peptide receptors (NPR), NPR-A and NPR-B, which are
coupled to the particulate guanylyl cyclase. ANP and BNP mainly
bind to NPR-A, while CNP functions via NPR-B [3].
Unlike ANP or BNP, CNP lacks a C-terminus amino acid
extension, which might account for its weakness of natriuretic
actions [4–6]. This limits the application of CNP against disorders
with sodium-and water-retaining syndromes, such as acute heart
failure (AHF) despite its attractive venodilating advantages
[6,7].To optimize the structure of natural NPs, strategy of proteins
engineering was advanced: to fuses beneficial structural elements
unique for one peptide with active structures from separate
peptides to create chimeras, which possess attractive therapeutic
properties of the parental molecules [8].
In 1993, Wei CM et al. [9] invented vasonatrin peptide (VNP),
the man-made novel member of the NPs family. VNP is a chimera
of CNP and ANP possessing the 22-amino acid ringed structure of
CNP, along with the C-terminus of ANP. VNP has the venodilating
actions of CNP, the natriuretic actions of ANP, and unique arterial
vasodilating actions not associated with either ANP or CNP. In
addition, Lisy O et al. [10] engineered the C-terminus of Dendroaspis
natriuretic peptide (DNP) to the structure of CNP and got a novel
NP, termed AD-NP. Demonstrated in vivo, CD-NP is natriuretic
and diuretic, glomerular filtration rate enhancing, cardiac unload-
ing, and renin inhibiting. However, DNP was originally isolated
from the green mamba. Its non-human origin challenged the safety
of its utility in human beings. Recently, Kilic A et al. [11] reported
CU-NP, a non-vasodilatating novel NP synthesized from the ring
structure of CNP and both C- and N-termini of urodilatin. CU-NP
had direct anti-hypertrophic effect on cultured neonatal rat
ventricular myocytes exposed to phenylephrine. Urodilatin is a
32-amino acid peptide generated from alternative processing of
ANP expressed in the kidney [12]. Inspire by the success of previous
reported chimericNPs, we designed an AC-NP,comprising the ring
structure of CNP along with C- and N-termini of ANP, and
identified its functional actions.
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Reagents
Figure 1 illustrates the structures of ANP, CNP, VNP, and the
new peptide, AC-NP. AC-NP is 28-amino acid in length including
17-amino acid ringed structure from CNP, as well as both C- and
N-termini of ANP. ANP, CNP, VNP and AC-NP were all
synthesized by School of Medicine and Pharmaceutics, Jiangnan
University (Wuxi, China). L-norepinephrine bitartrate (NE) and
acetylcholine chloride (Ach) were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). [
125I]-cGMP assay kit was from
Shanghai Chinese Medical University (Shanghai, China).
Animals
Animal experiments were approved by University Ethics
Committee (the Ethical Committee of Fourth Military Medical
University on research with approval ID 2010-jxsyzx-1). Prior to
the experiments, male Sprague-Dawley (SD) rats (250–350 g body
weight; 6–8 weeks old) had been reared at an ambient temperature
of 2361uC and a relative humidity of 60–70%, with light exposure
daily from 6:00 to 18:00 h. Each animal received a standard
laboratory diet and tap water ad libitum throughout the
experimental period.
Arterial Ring Preparation and Vasoreactivity
Measurement
Rings cut from abdominal aorta obtained from male SD rats
(anesthetized with 40 mg/kg sodium pentobarbital intra perito-
nealy) were suspended for the measurement of isometric force in
organ chambers filled with Krebs solution, maintained at 37uC
and bubbled with a gas mixture of 95% O2-5% CO2 [13].The
Krebs solution contained (in 10
23 M) 115 NaCl, 4.7 KCl, 25
NaHCO3,1 . 2M g C l 2,1 . 2K H 2PO4,2 . 5C a C l 2, and 10 glucose;
pH 7.4. In one-half of the rings, the endothelium was removed by
gently rubbing the intimal surface with a cotton swab wet with
control solution. For each individual vessel ring, the proper
length-tension relationship during repeated exposures to 10
21 M
KCl was determined by 100-mg increments until an optimal
resting force around 500 mg was identified. All the subsequent
pharmacological examinations were conducted at this initial
resting force.
Experimental procedure is as follows. After 30 min of
equilibration, the presence of functional endothelium was
determined at the beginning of the experiment by relaxation to
Ach (10
26 M) during a contraction to NE (10
26 M) at optimal
length. In order to study the vasorelaxant properties of ANP,
CNP, VNP or AC-NP, the artery segments were initially
contracted with NE (10
26 M), which elicited 80% of maximal
contraction. When the contraction reached a steady state,
cumulative concentration-response curves to ANP, CNP, VNP
or AC-NP were obtained by adding increasing logarithmic molar
concentrations. The maximal contraction induced by 10
26 M
extracellular NE was arbitrarily set as 100%. Relaxation produced
by AC-NP, ANP, CNP or VNP was measured and expressed as
the reduced percentages of maximal contractile amplitudes to
10
26 M NE.
Figure 1. Amino acid sequences and structures of human ANP (h-ANP), human CNP (h-CNP), chimeric VNP and novel chimeric
AC-NP.
doi:10.1371/journal.pone.0020477.g001
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Experiments were conducted in four groups (n=6): ANP, CNP,
VNP or AC-NP. SD rats were anesthetized with 40 mg/kg sodium
pentobarbital intra peritonealy. Intravenous infusions of saline
solution (0.9% NaCl) were performed (1 ml/100 gm body weight
per hour) through the left jugular vein catheter. After completion
of surgery, rats were allowed to stabilize for 30 min. In each group
a 15 min baseline period followed. After the baseline period, the
NPs (ANP, CNP, VNP, AC-NP) at 50 mg/kg or saline vehicle
(0.9% NaCl) was administered in a bolus fashion (0.1 ml) and was
followed by a 15-min period. After a 30-min washout, a 15-min
recovery period followed.
During each experimental period, carotid arterial pressure
(mCAP) was recorded via left carotid artery cannulation by the
BL-420F BioData Acquisition & Analysis Systems (TME Tech-
nology Co, Ltd, Chengdu, China). At the midpoint of baseline and
bolus, blood was sampled for analysis of plasma cGMP levels
(PcGMP). At the end of baseline, and bolus period, urine collected
for determination of urine volume (UV), urine sodium excretion
(UNaV, by zeeman atomic absorption spectroscopy) and urine
cGMP excretion (UcGMPV).
Blood for plasma cGMP analysis was collected into EDTA
tubes, immediately placed on ice, and centrifuged at 2,500 rpm at
4uC. Plasma was separated and stored at 220uC until assay. Urine
for cGMP determination was heated to over 90uC before storage.
The levels of cGMP were determined by radioimmunoassay
performed with a [
125I]-cGMP assay kit previously described [14].
The sensitivities of the cGMP radioimmunoassay were 50 fmol per
assay tube.
Statistical Analysis
Data are expressed as the mean6SEM. Significant differences
between the means were determined by one-way analysis of
variance (ANOVA). If significant, group means were compared
using Least significant difference (LSD) methods for multiple
comparisons of means. Statistical significance was determined by a
P,0.05, calculated by SPSS, version 13.0 (SPSS Science, Chicago,
IL, USA).
Results
As shown in Figure 1, both AC-NP and VNP are the chimeras
of ANP and CNP. Structurally, ANP and CNP are the ‘‘parents’’
of AC-NP, whereas VNP and AC-NP are ‘‘brothers’’. Allowing for
the structural similarity of AC-NP, ANP, CNP and VNP, we
therefore evaluated the actions of AC-NP compared with ANP,
CNP and VNP.
In Vitro Vasorelaxing Actions of AC-NP in Isolated
Abdominal Aorta from Rat
In the representative concentration-response curves illustrated
in Figure 2A, AC-NP reduced the contractile responses of the
arterial ring to 10
26 M NE in a dose dependent manner. The
equivalent responses of deendothelium and endothelium-intact
Figure 2. Relaxant responses of isolated abdominal aorta from rat to ANP, CNP, VNP or AC-NP. Endothelium-intact rings cut from
abdominal aorta of 5 rats (n=5) were suspended in organ chambers. In one-half of the rings, the endothelium was removed by gently rubbing the
intimal surface with a cotton swab. After setting resting force to about 500 mg weight, artery rings were contracted with 10
26 M extracellular
norepinephrine (NE) and relaxed with ANP, CNP, VNP or AC-NP. (A) The representative curves of relaxation to cumulatively increasing concentration
of AC-NP. (B) Dose dependent response of isolated rat abdominal aorta with or without endothelium to cumulatively increasing concentration of AC-
NP. (C) Maximal responses to ANP, CNP, VNP and AC-NP at the dose of 10
26 M, or saline as control. The maximal contraction induced by 10
26 M
extracellular NE was arbitrarily set as 100%. Data of relaxation are the reduced (minus) percentages of maximal contractile amplitudes to 10
26 M NE,
and presented as mean 6 SEM. Symbols obscure some of the smaller error bars.
doi:10.1371/journal.pone.0020477.g002
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NP are independent of endothelium (Fig. 2B). The maximal
relaxations induced by ANP, CNP, VNP or AC-NP in isolated rat
abdominal aorta were shown in Figure 2C. ANP, CNP, VNP or
AC-NP at the dose of 10
26 M all caused significant relaxations
compared with saline control (P,0.05, n=5). The potency for
relaxation in isolated rat abdominal aorta for the peptides was
shown as: CNP . AC-NP . VNP . ANP, but not statistically
significant.
In Vivo Cardiorenal Actions of AC-NP in Rats
In accordance with the in vitro evidences, ANP, CNP, VNP or
AC-NP at the dose of 10
26 M all induced significant decrease of
mCAP in comparison with the level of baseline (P,0.05, n=6).
The decreased percentage of ANP, CNP, VNP and AC-NP was
24%, 15%, 29% and 44% indicating potential hypotensive effects
of AC-NP (Fig. 3).
Also we observed potent natriuretic and diuretic responses to
AC-NP in normal rats (Table 1). ANP, VNP and AC-NP all
markedly enhanced the UV and UNa, in contrast to the non-
obvious effects of CNP (P,0.05, n=6). Importantly, AC-NP
caused greater responses of both urine volume and urine sodium
excretion compared with ANP and VNP. Thus, the natriuretic
and diuretic responses to NPs were summarized as: AC-NP .
ANP . VNP . CNP.
NPRA/B/cGMP/PKG is the classical signaling pathway
participating the bioactivities of NPs in cardiovascular and renal
system [3]. Therefore, the levels of cGMP in urine as well as in the
plasma were detected after treatment of rats with NPs. As shown in
Figure 4, the enhancing effects on the levels of plasma cGMP
induced by AC-NP were greatest among the NPs tested in current
Figure 3. Effect of AC-NP on mean carotid arterial pressure
(mCAP) in rats. The mCAP values were normalized against the
corresponding values of baseline, which were arbitrarily set as 1. Data
are expressed as means 6 SEM, n=6. *P,0.05 versus baseline.
# P,0.05 versus ANP, CNP, or VNP group. Saline was used as control.
doi:10.1371/journal.pone.0020477.g003
Table 1. Effects of AC-NP, ANP, CNP and VNP on UV and
UNaV after intravenous injection in anesthetized rats (n=6,
mean 6 SEM).
Natriuretic peptides (50 mg/kg) UV (ml/min)
UNaV
(mmol/min)
ANP Baseline 7.461.1 0.660.1
Treatment 28.962.2* 2.660.4*
CNP Baseline 7.860.9 0.860.2
Treatment 7.460.8 0.860.1
VNP Baseline 8.761.2 0.960.2
Treatment 19.261.8* 2.560.3*
AC-NP Baseline 7.560.9 0.760.1
Treatment 75611.4*,# 7.160.7*,#
Note: UV, urine volume; UNaV, urine sodium excretion.
*P,0.01 versus the baseline levels.
#P,0.05 versus the levels of ANP, CNP or VNP-treated group.
doi:10.1371/journal.pone.0020477.t001
Figure 4. Responses of plasma cGMP levels (PcGMP) and urine
cGMP excretion (UcGMPV) to ANP, CNP, VNP and AC-NP. Rats
were treated with ANP, CNP, VNP or AC-NP (50 mg/kg). The levels of
cGMP in plasma (A) or urine cGMP excretion (B) were determined by
radioimmunity assay. The cGMP levels of baseline group were arbitrarily
set as 1. Data represent mean6SEM, n=6. * P,0.05 versus baseline,
# P,0.05 versus CNP or VNP group.
doi:10.1371/journal.pone.0020477.g004
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significantly stronger than that of CNP or VNP (P,0.05, n=6).
Discussion
This study reports for the first time the cardiorenal actions of a
new chimera derived from ANP and CNP. Termed AC-NP, the
novel NP represents the 17-amino acid ringed structure of CNP
along with the C- and N-termini of ANP. Functionally, AC-NP
proved to be a potent vasorelaxing peptide similar to ANP, CNP
and VNP. Specifically, AC-NP was more potently natriuretic and
diuretic compared with ANP and VNP, contrast to the reported
lack of significant renal actions of CNP [4,6,7]. The diuretic
activity of AC-NP might contribute to its hypotensive effects.
The structural difference between ANP and CNP (Fig. 1) is in
amino acid sequences and an absence of a C-terminus for CNP as
noted for ANP. As for AC-NP, its C-terminus was from ANP. In a
similar way, another chimeric NP, VNP, also adds C-terminus of
ANP to the ringed structure of CNP. However, the N-terminus of
VNP was that of CNP rather that of ANP. This is the structural
difference between AC-NP and VNP. Our current work (Fig. 4)
and previous reports on VNP [9] give evidences that addition of
C-terminus to the ring of CNP results in gain of natriuretic
functions. Importantly, engineering of termini of ANP and ring of
CNP in AC-NP supports the conclusion that both C- and N-
termini might play a functionally important role for biological
activity of NPs. As a result, chimeric NPs including ACP-NP, VNP
[9], and recently reported AD-NP [10], CU-NP [11] gain
beneficial properties in comparison with their parental NPs. It
suggested that engineering of chimeric NPs is a feasible strategy to
optimize the structure of NPs for the sake of clinical applications.
In current study, we identified some cardiorenal actions of AC-
NP. However, the mechanism of this new NP is largely unknown.
Since cGMP is the classical second messenger of NPs-NPR-
cGMP-PKG signaling pathway [3], AC-NP-induced elevation of
plasma and urine cGMP levels suggests participating roles of
cGMP in the action of AC-NP. It is known that ANP and BNP
mainly bind to NPR-A, while CNP functions via NPR-B [2]. As
the chimera of ANP and CNP, AC-NP possibly plays roles via
NPR-A or NPR-B. It was reported that functional receptor
subtypes for VNP, another chimera of ANP and CNP, in renal
glomeruli and arteries was NPR-A [15]. Allowing for the
homology between VNP and AC-NP, AC-NP is likely to act on
NPR-A. However, our present study could not exclude the
possibility of the participation of NPR-B in the function of AC-NP,
further studies are required to give direct evidence.
In summary, we reported the design, synthesis, and cardiorenal
actions AC-NP, a novel man-made NP, which represents a fusion
peptide of the full-length 22-amino acid structure of CNP together
with both C- and N-termini of ANP. Specifically, AC-NP
demonstrated vasorelaxing, natriuretic and diuretic advantages
compared with previously reported ANP, CNP and VNP. The
properties of AC-NP especially suggests its possible usefulness
against cardiorenal disorders with sodium-and water-retaining
such as acute heart failure and acute myocardial infarction.
Further intensive investigations of AC-NP in experimental models
of cardiorenal disease and ultimately in human disease states will
answer the question of whether this new NP will indeed act as
efficacious and safe drugs.
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